Clinical trial
Urokinase Plasminogen Activator System in Benign Prostatic Hyperplasia
NCT00407329 · Queen's University, Other · Completed
Key facts
| NCT number | NCT00407329 |
|---|---|
| Title | Urokinase Plasminogen Activator System in Benign Prostatic Hyperplasia |
| Official title | Urokinase Plasminogen Activator System in Benign Prostatic Hyperplasia: A Possible Marker of Progression and Response to Medical Therapy |
| Lead sponsor | Queen's University, Other |
| Status | Completed |
| Study type | Observational |
| Conditions | BPH |
| Intervention type | Procedure |
| Interventions | transurethral resection of the prostate |
| Enrollment | 30 |
| Start date | Nov 1, 2006 |
| Primary completion | Feb 1, 2008 |
| Completion | Jan 1, 2012 |
| First posted | Dec 5, 2006 |
| Last update posted | Nov 6, 2013 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: